300 related articles for article (PubMed ID: 31190581)
1. Cost-effectiveness of
Kowada A
Scand J Gastroenterol; 2019 Jun; 54(6):685-689. PubMed ID: 31190581
[No Abstract] [Full Text] [Related]
2. Cost-effectiveness of Helicobacter pylori screening followed by eradication treatment for employees in Japan.
Kowada A
Epidemiol Infect; 2018 Oct; 146(14):1834-1840. PubMed ID: 30056808
[TBL] [Abstract][Full Text] [Related]
3. Endoscopy Is Cost-Effective for Gastric Cancer Screening After Successful Helicobacter pylori Eradication.
Kowada A
Dig Dis Sci; 2021 Dec; 66(12):4220-4226. PubMed ID: 33417196
[TBL] [Abstract][Full Text] [Related]
4. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding.
Leontiadis GI; Sreedharan A; Dorward S; Barton P; Delaney B; Howden CW; Orhewere M; Gisbert J; Sharma VK; Rostom A; Moayyedi P; Forman D
Health Technol Assess; 2007 Dec; 11(51):iii-iv, 1-164. PubMed ID: 18021578
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness analysis of population-based serology screening and (13)C-Urea breath test for Helicobacter pylori to prevent gastric cancer: a markov model.
Xie F; Luo N; Lee HP
World J Gastroenterol; 2008 May; 14(19):3021-7. PubMed ID: 18494053
[TBL] [Abstract][Full Text] [Related]
6. A screening program to test and treat for Helicobacter pylori infection: Cost-utility analysis by age, sex and ethnicity.
Teng AM; Kvizhinadze G; Nair N; McLeod M; Wilson N; Blakely T
BMC Infect Dis; 2017 Feb; 17(1):156. PubMed ID: 28219322
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of screen-and-treat strategy in asymptomatic Chinese for preventing Helicobacter pylori-associated diseases.
Chen Q; Liang X; Long X; Yu L; Liu W; Lu H
Helicobacter; 2019 Apr; 24(2):e12563. PubMed ID: 30672082
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness Analysis of Helicobacter pylori Eradication Therapy for Prevention of Gastric Cancer: A Markov Model.
Han Y; Yan T; Ma H; Yao X; Lu C; Li Y; Li L
Dig Dis Sci; 2020 Jun; 65(6):1679-1688. PubMed ID: 31673902
[TBL] [Abstract][Full Text] [Related]
9. Economic and health impacts of introducing Helicobacter pylori eradication strategy into national gastric cancer policy in Japan: A cost-effectiveness analysis.
Kowada A; Asaka M
Helicobacter; 2021 Oct; 26(5):e12837. PubMed ID: 34278663
[TBL] [Abstract][Full Text] [Related]
10. Gastric adenocarcinoma screening and prevention in the era of new biomarker and endoscopic technologies: a cost-effectiveness analysis.
Yeh JM; Hur C; Ward Z; Schrag D; Goldie SJ
Gut; 2016 Apr; 65(4):563-74. PubMed ID: 25779597
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of Helicobacter pylori screening in prevention of gastric cancer in Chinese.
Xie F; Luo N; Blackhouse G; Goeree R; Lee HP
Int J Technol Assess Health Care; 2008; 24(1):87-95. PubMed ID: 18218173
[TBL] [Abstract][Full Text] [Related]
12. The cost effectiveness of Helicobacter pylori population screening-economic evaluation alongside a randomised controlled trial with 13-year follow-up.
Høgh MB; Kronborg C; Hansen JM; Schaffalitzky de Muckadell OB
Aliment Pharmacol Ther; 2019 Apr; 49(8):1013-1025. PubMed ID: 30854700
[TBL] [Abstract][Full Text] [Related]
13. Clinical and economic effects of population-based Helicobacter pylori screening to prevent gastric cancer.
Fendrick AM; Chernew ME; Hirth RA; Bloom BS; Bandekar RR; Scheiman JM
Arch Intern Med; 1999 Jan; 159(2):142-8. PubMed ID: 9927096
[TBL] [Abstract][Full Text] [Related]
14. Family-based Helicobacter pylori infection control and management strategy and screen-and-treat strategy are highly cost-effective in preventing multiple upper gastrointestinal diseases in Chinese population at national level.
Zhang C; Qi YB; Hu RB; Xu L; Li XT; Ma J; Shao QQ; Abdun MA; Ur Rahman I; Shi WJ; Li FQ; Yu JJ; Yuan MK; Chen Q; Lu H; Ding SZ
Helicobacter; 2024; 29(3):e13063. PubMed ID: 38874128
[TBL] [Abstract][Full Text] [Related]
15. [Cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: Markov decision analysis].
Wang Q; Jin PH; Lin GW; Xu SR; Chen J
Zhonghua Liu Xing Bing Xue Za Zhi; 2003 Feb; 24(2):135-9. PubMed ID: 12697117
[TBL] [Abstract][Full Text] [Related]
16. Screening for gastric cancer and surveillance of premalignant lesions: a systematic review of cost-effectiveness studies.
Areia M; Carvalho R; Cadime AT; Rocha Gonçalves F; Dinis-Ribeiro M
Helicobacter; 2013 Oct; 18(5):325-37. PubMed ID: 23566268
[TBL] [Abstract][Full Text] [Related]
17. The cost-effectiveness of population Helicobacter pylori screening and treatment: a Markov model using economic data from a randomized controlled trial.
Mason J; Axon AT; Forman D; Duffett S; Drummond M; Crocombe W; Feltbower R; Mason S; Brown J; Moayyedi P;
Aliment Pharmacol Ther; 2002 Mar; 16(3):559-68. PubMed ID: 11876711
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of population screening for Helicobacter pylori in preventing gastric cancer and peptic ulcer disease, using simulation.
Roderick P; Davies R; Raftery J; Crabbe D; Pearce R; Patel P; Bhandari P
J Med Screen; 2003; 10(3):148-56. PubMed ID: 14561268
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis between primary and secondary preventive strategies for gastric cancer.
Lee YC; Lin JT; Wu HM; Liu TY; Yen MF; Chiu HM; Wang HP; Wu MS; Hsiu-Hsi Chen T
Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):875-85. PubMed ID: 17507609
[TBL] [Abstract][Full Text] [Related]
20. Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials.
Parsonnet J; Harris RA; Hack HM; Owens DK
Lancet; 1996 Jul; 348(9021):150-4. PubMed ID: 8684154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
